The ECMO PK Project: An incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation

BMC Anesthesiology

Volumn 13, Issue , 2013, Pages

  Shekar, Kiran ^a   Roberts, Jason A ^a   Smith, Maree T ^a   Fung, Yoke L ^a   Fraser, John F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Extracorporeal membrane oxygenation; Pharmacodynamics; Pharmacokinetics; Therapeutic failure; Toxicity

Indexed keywords

BUPRENORPHINE; CASPOFUNGIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; DEXMEDETOMIDINE; FENTANYL; FLUCONAZOLE; GENTAMICIN; LINEZOLID; MEROPENEM; MIDAZOLAM; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; PROPOFOL; THIOPENTAL; TIMENTIN; VANCOMYCIN; VORICONAZOLE;

ARTICLE; BLOOD SAMPLING; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TREATMENT FAILURE; EX VIVO STUDY; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; HUMAN; HUMAN TISSUE; MORBIDITY; NONHUMAN; PHARMACOKINETICS; PRACTICE GUIDELINE; SEDATION; SHEEP;

EID: 84875186438     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-13-7     Document Type: Article

References (50)

1. Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol 2010, 76(7):534-540.
2. Fraser JFSK, Diab S, Foley SR, McDonald CI, Passmore M, Simonova G, Roberts JA, Platts DG, Mullany DV, Fung YL. ECMO - the clinician's view. ISBT Science Series 2012, 7:82-88.
3. MacLaren G. Lessons in advanced extracorporeal life support. Crit Care Med 2012, 40(9):2729-2731. 10.1097/CCM.0b013e31825ae6dc, 22903106.
4. MacLaren G. Evidence and experience in extracorporeal membrane oxygenation. Chest 2011, 139(4):965. author reply 965-966.
5. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Ziegenfuss M, Smith MT, Fung YL, Fraser JF. Sedation during extracorporeal membrane oxygenation-why more is less. Anaesth Intensive Care 2012, 40(6):1067-1069.
6. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Wallis SC, Smith MT, Fraser JF. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. J Antimicrob Chemother 2013, 68(3):726-7. March, 10.1093/jac/dks435, 23111850.
7. Shekar K, Roberts JA, Mullany DV, Corley A, Fisquet S, Bull TN, Barnett AG, Fraser JF. Increased sedation requirements in patients receiving extracorporeal membrane oxygenation for respiratory and cardiorespiratory failure. Anaesth Intensive Care 2012, 40(4):648-655.
8. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012, 27(6):741 e749-741 e718.
9. Roberts DM RJ, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy - a multicentre pharmacokinetic study. Crit Care Med 2012, 40(5):1523-8. May, 10.1097/CCM.0b013e318241e553, 22511133.
10. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts JA. Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012, 142(1):30-9. July, 10.1378/chest.11-1671, 22194591.
11. Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 2011, 55(12):5868-5873. 10.1128/AAC.00424-11, 3232768, 21930888.
12. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55(6):2704-2709. 10.1128/AAC.01708-10, 3101407, 21402850.
13. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003, 42(5):403-417. 10.2165/00003088-200342050-00001, 12739981.
14. Mulla HGL, Firmin RK, David RU. Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatric and Perinatal Drug Therapy 2001, 4(3):109-120.
15. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010, 36(12):2109-2116. 10.1007/s00134-010-2041-z, 2981740, 20862453.
16. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1992, 12(1):28-32.
17. Rosen DA, Rosen KR, Silvasi DL. In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth 1990, 4(3):332-335. 10.1016/0888-6296(90)90041-D, 2131883.
18. Mulla H, Lawson G, von Anrep C, Burke MD, Upton DU, Firmin RK, Killer H. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 2000, 15(1):21-26. 10.1177/026765910001500104, 10676864.
19. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, Roberts MJ, Kruger P, Lipman J. Antibiotic dosing in the 'at risk' critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011, 11:3. 10.1186/1471-2253-11-3, 3050838, 21333028.
20. Roberts JA, Joynt GM, Choi GY, Gomersall CD, Lipman J. How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2012, 39(3):187-92. March, 10.1016/j.ijantimicag.2011.11.002, 22226651.
21. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 2011, 12(12):2070-9. Dec, 10.2174/138920111798808329, 21554211.
22. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000, 342(20):1471-1477. 10.1056/NEJM200005183422002, 10816184.
23. Patel SB, Kress JP. Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med 2012, 185(5):486-497. 10.1164/rccm.201102-0273CI, 22016443.
24. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2010, 49(6):407-419. 10.2165/11319970-000000000-00000, 20481651.
25. Dagan O, Klein J, Bohn D, Koren G. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med 1994, 22(7):1099-1101. 10.1097/00003246-199407000-00008, 8026197.
26. Mulla H, Lawson G, Peek GJ, Firmin RK, Upton DR. Plasma concentrations of midazolam in neonates receiving extracorporeal membrane oxygenation. ASAIO J 2003, 49(1):41-47. 10.1097/00002480-200301000-00007, 12558306.
27. Jackson DL, Proudfoot CW, Cann KF, Walsh T. A systematic review of the impact of sedation practice in the ICU on resource use, costs and patient safety. Crit Care 2010, 14(2):R59. 10.1186/cc8956, 2887180, 20380720.
28. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64(1):142-150. 10.1093/jac/dkp139, 19398460.
29. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance-what's dosing got to do with it?. Crit Care Med 2008, 36(8):2433-2440. 10.1097/CCM.0b013e318180fe62, 18596628.
30. Roberts JA, Lipman J. Optimizing use of beta-lactam antibiotics in the critically ill. Semin Respir Crit Care Med 2007, 28(6):579-585. 10.1055/s-2007-996404, 18095221.
31. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45(8):755-773. 10.2165/00003088-200645080-00001, 16884316.
32. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med 2011, 12(3):277-281. 10.1097/PCC.0b013e3181e28894, 20495508.
33. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J 1990, 9(8):562-566. 10.1097/00006454-199008000-00007, 2122409.
34. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993, 15(4):263-266. 10.1097/00007691-199308000-00001, 8236359.
35. Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994, 16(6):552-559. 10.1097/00007691-199412000-00004, 7878693.
36. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans 1991, 37(1):16-18. 10.1097/00002480-199101000-00006, 2012712.
37. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1989, 33(6):817-819. 10.1128/AAC.33.6.817, 284237, 2764529.
38. Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, Ghassabian S, Wallis SC, Fung YL, Smith MT. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 2012, 16(5):R194. 10.1186/cc11679, 23068416.
39. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR, Fisquet S, Platts DG, Stewart D, Wallis SC. Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Crit Care Resusc 2012, 14(2):105-111.
40. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006, 45(7):705-714. 10.2165/00003088-200645070-00005, 16802851.
41. Hayes RA SK, Fraser JF. Is hyperoxaemia helping or hurting patients during extracorporeal membrane oxygenation? Review of a complex problem. Perfusion 2012, In press.
42. Rump AF, Siekmann U, Kalff G. Effects of hyperbaric and hyperoxic conditions on the disposition of drugs: theoretical considerations and a review of the literature. Gen Pharmacol 1999, 32(1):127-133. 10.1016/S0306-3623(98)00074-3, 9888265.
43. van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010, 49(5):277-294. 10.2165/11319360-000000000-00000, 20384391.
44. Wildschut ED, van Saet A, Pokorna P, Ahsman MJ, Van den Anker JN, Tibboel D. The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin North Am 2012, 59(5):1183-1204. 10.1016/j.pcl.2012.07.013, 23036251.
45. Riedel T, Fraser JF, Dunster K, Fitzgibbon J, Schibler A. Effect of smoke inhalation on viscoelastic properties and ventilation distribution in sheep. J Appl Physiol 2006, 101(3):763-770. 10.1152/japplphysiol.01635.2005, 16627672.
46. The acute respiratory distress syndrome network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000, 342(18):1301-1308. The acute respiratory distress syndrome network.
47. Platts DG, Sedgwick JF, Burstow DJ, Mullany DV, Fraser JF. The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation. J Am Soc Echocardiogr 2012, 25(2):131-141. 10.1016/j.echo.2011.11.009, 22169046.
48. Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, Ghassabian S, Wallis SC, Levkovich B, Pellegrino V. ASAP ECMO: antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol 2012, 12(1):29. 10.1186/1471-2253-12-29, 3543712, 23190792.
49. DMullany TB, Hunt B, Shekar K, Thomson B, Fraser JF, Ziegenfuss M. Outcomes of the first 30 cases of the adult ECMO program: strategies to manage the " learning curve" and implications for ICU risk adjustment models. Crit Care Resusc 2011, Accepted for publication.
50. Ghassabian S, Moosavi SM, Valero YG, Shekar K, Fraser JF, Smith MT. High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 903:126-133.